HeMemics Biotechnologies Overview

  • Founded

  • 2007

Founded
  • Status

  • Private

  • Employees

  • 12

Employees
  • Latest Deal Type

  • Later Stage VC

  • Latest Deal Amount

  • $100K

  • Investors

  • 5

HeMemics Biotechnologies General Information

Description

Developer of a cell preservation platform designed to dehydrate cells in a dried or partially dried format for wider distribution and ease of use. The company's platform helps preserve mammalian cells and biologics in desiccated and non-desiccated formats in cold or ambient temperature instead of a frozen format, thereby enabling medical practitioners to stabilize cells to reduce protein damage and improve the ease of storage, transport, and shelf-life.

Contact Information

Website
www.hememics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Primary Office
  • 401 Professional Drive
  • Suite 220
  • Gaithersburg, MD 20879-3445
  • United States
+1 (240) 000-0000

HeMemics Biotechnologies Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HeMemics Biotechnologies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 14-Dec-2020 $100K 00.000 Completed Generating Revenue
7. Secondary Transaction - Private 00.000 Completed Generating Revenue
6. Seed Round 11-Dec-2019 00.00 00.000 00.00 Completed Generating Revenue
5. Angel (individual) 25-May-2018 00000 00000 Completed Startup
4. Seed Round 18-Dec-2017 00000 00000 00.000 Completed Startup
3. Accelerator/Incubator 01-Dec-2017 00000 Completed Startup
2. Grant 01-Jan-2012 $185K $107K Completed Startup
1. Accelerator/Incubator 13-Aug-2007 $107K $107K Completed Startup
To view HeMemics Biotechnologies’s complete valuation and funding history, request access »

HeMemics Biotechnologies Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed 2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Seed 1 0,000,000 00.000000 00.00 00.00 00 00.00 0.000
To view HeMemics Biotechnologies’s complete cap table history, request access »

HeMemics Biotechnologies Patents

  • 18

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

HeMemics Biotechnologies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3861330-A1 Biosensors using carbon nanotubes and an electronic reader for use with the biosensors Pending 05-Oct-2018 00000000000
US-9943075-B2 Preservation solutions for biologics and methods related thereto Active 17-Feb-2010 000000000 00
US-20130059380-A1 Preservation solutions for biologics and methods related thereto Granted 17-Feb-2010 000000000 0
EP-2547760-A1 Preservation solutions for biologics and methods related thereto Withdrawn 17-Feb-2010 000000000 0
US-20150157009-A1 Preservation solutions for biologics and methods related thereto Abandoned 17-Feb-2010 A01N1/021
To view HeMemics Biotechnologies’s complete patent history, request access »

HeMemics Biotechnologies Executive Team (8)

Name Title Board Seat Contact Info
John Warden Jr. Co-Founder, Chief Executive Officer, Chief Operating Officer & Board Member
David Ho Ph.D Co-Founder, Chief Scientific Officer, President & Board Member
Bruce Campbell Executive Officer & Board Member
James Hogarty Executive Officer & Board Member
Brandon Ho Executive Officer
You’re viewing 5 of 8 executive team members. Get the full list »

HeMemics Biotechnologies Board Members (12)

Name Representing Role Since
Bruce Campbell HeMemics Biotechnologies Executive Officer & Board Member 000 0000
David Ho Ph.D HeMemics Biotechnologies Co-Founder, Chief Scientific Officer, President & Board Member 000 0000
Hao Nguyen Self Board Member 000 0000
Hoa Nguyen Ph.D Self Board Member 000 0000
James Hogarty HeMemics Biotechnologies Executive Officer & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

HeMemics Biotechnologies Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HeMemics Biotechnologies Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
American Vietnamese Investment Partners Venture Capital Minority 000 0000 000000 0
Inova Strategic Investments Corporate Venture Capital Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Maryland Industrial Partnerships University Minority 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view HeMemics Biotechnologies’s complete investors history, request access »

Ready to get started?

Request a free trial